Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 2/2008

01-02-2008 | Original Paper

Potential Role of Apoptosis and Apoptotic Regulatory Proteins in Colorectal Neoplasia: Correlations with Clinico-Pathological Parameters and Survival

Authors: Maria Tzouvala, Andreas C. Lazaris, George V. Papatheodoridis, Chariklia Kouvidou, Thomas G. Papathomas, Nikos Kavantzas, Ioannis Elemenoglou, Demetrios G. Karamanolis, Emmanouil Agapitos

Published in: Digestive Diseases and Sciences | Issue 2/2008

Login to get access

Abstract

An imbalance between apoptotic and proliferative processes is believed to underlie colorectal neoplasia. We evaluated the expression of bcl-2, p53, mdm2 proteins, and apoptosis in colorectal neoplasms, as well as their correlation with clinico-pathological parameters, using image analysis. Biopsies from 46 colorectal cancers, 121 adenomas, and 25 controls were studied using monoclonal antibodies against p53, bcl-2, mdm2 and the terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling (TUNEL) method for apoptosis. P53 and bcl2 protein expression was higher in adenomas ≥1 cm (P < 0.03) and tubulovillous-villous adenomas (P < 0.03), and correlated with dysplasia (P < 0.03). In Cox regression analysis, Dukes’ stage was the most significant independent prognostic indicator of a worse survival (P < 0.019), whereas when stage was eliminated, bcl-2 expression was also a powerful predictor for bad prognosis (P = 0.02).
In conclusion, both bcl-2 and p53 immunohistochemical profiles may be useful adjuncts in detecting adenomas with a malignant potential, whereas bcl-2 could be used in combination with Dukes’ stage as a predictor of prognosis in colorectal cancer.
Literature
1.
Sternberg SS (1997) Apoptosis. In: Thaw VE, Hummel JE, Bass LB, Josephson D, (eds) Histology for pathologists. Lippincott Williams & Wilkins, Philadelphia, pp 3–21
2.
3.
4.
Butler LM, Hewett PJ, Fitridge RA, Cowled PA (1999) Deregulation of apoptosis in colorectal carcinoma: theoretical and therapeutic implications. Aust NZ J Surg 69:88–94CrossRef
5.
Elkablawy MA, Maxwell P, Williamson K, Anderson N, Hamilton PW (2001) Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma: relationship to tumour stage and patient survival. J Pathol 194:436–443PubMedCrossRef
6.
Maritsi D, Stagikas D, Charalabopoulos K, Batistatou A (2006) What’s new in p53. Hippokratia 10:116–119PubMed
7.
Broll R, Stark A, Windhovel U, Best R, Strik MW, Schimmelpenning H, Schwandner O, Kujath P, Bruch HP, Duchrow M (1999) Expression of p53 and mdm2 mRNA and protein in colorectal carcinomas. Eur J Cancer 35:1083–1088PubMedCrossRef
8.
Paradiso A, Ranieri G, Simone G, Silvestris N, Costa A, De Lena M, Leone A, Vallejo C, Lacava J (2002) mdm2-p53 interaction: lack of correlation with the response to 5-Fluorouracil in advanced colorectal cancer. Oncology 62:278–285PubMedCrossRef
9.
Montgomery EA (2006) Colon: polyps, tumors, and tumefactions. In: Pine JW, Jacobs AE (eds) Biopsy interpretation of the gastrointestinal tract mucosa, Lippincott Williams & Wilkins, Philadelphia, pp 269–316
10.
Fenoglio-Preiser CM (1999) Carcinomas and other epithelial and neuroendocrine tumors of the large intestine. In: AS Patterson M Iannuzzi L Carita (eds) Gastrointestinal pathology: an atlas and text. Lippincott Williams & Wilkins, Philadelphia, pp 909–1068
11.
Watson AJ, Merritt AJ, Jones LS, Askew JN, Anderson E, Becciolini A, Balzi M, Potten CS, Hickman JA (1996) Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer 73:889–895PubMed
12.
Hao X, Du M, Bishop AE, Talbot IC (1998) Imbalance between proliferation and apoptosis in the development of colorectal carcinoma. Virchows Arch 433:523–527PubMedCrossRef
13.
Saleh HA, Jackson H, Banerjee M (2000) Immunohistochemical expression of bcl-2 and p53 oncoproteins: correlation with Ki67 proliferation index and prognostic histopathologic parameters in colorectal neoplasia. Appl Immunohistochem Mol Morphol 8:175–182PubMedCrossRef
14.
Goussia AC, Ioachim E, Agnantis NJ, Mahera M, Tsianos EV (2000) Bcl-2 expression in colorectal tumours. Correlation with p53, mdm-2, Rb proteins and proliferation indices. Histol Histopathol 15:667–672PubMed
15.
Han HS, Park YM, Hwang TS (2006) Differential expression of BCL-2, Bcl-XL and p53 in colorectal cancer. J Gastroenterol Hepatol 21:1108–1114PubMedCrossRef
16.
Scopa CD, Tsamandas AC, Zolota V, Kalofonos HP, Batistatou A, Vagianos C (2003) Potential role of bcl-2 and Ki-67 expression and apoptosis in colorectal carcinoma: a clinicopathologic study. Dig Dis Sci 48:1990–1997PubMedCrossRef
17.
Bhatavdekar JM, Patel DD, Ghosh N, Chikhlikar PR, Trivedi TI, Suthar TP, Doctor SS, Shah NG, Balar DB (1997) Co-expression of bcl-2, c-Myc and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 40:785–790PubMedCrossRef
18.
Srivastava S, Verma M, Henson DE (2001) Biomarkers for early detection of colon cancer. Clin Cancer Res 7:1118–1126PubMed
19.
Sinicrope FA, Hart J, Michelassi F, Lee JJ (1995) Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res 1:1103–1110PubMed
20.
Kouvidou C, Stefanaki K, Dai Y, Tzardi M, Koutsoubi K, Darivianaki , Karidi E, Rontogianni D, Zois E, Kakolyris S, Georgoulias V, Delides G, Kanavaros P (1997) P21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and MDM-2 protein expression. Anticancer Res 17:2615–2619PubMed
21.
Kaklamanis L, Savage A, Mortensen N, Tsiotos P, Doussis-Anagnostopoulou I, Biddolph S, Whitehouse R, Harris AL, Gatter KC (1996) Early expression of bcl-2 protein in the adenoma-carcinoma sequence. J Pathol 179:10–14PubMedCrossRef
22.
Bosari S, Moneghini L, Graziani D, Lee AK, Murray JJ, Coggi G, Viale G (1995) Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol 26:534–540PubMedCrossRef
23.
Watson NF, Madjd Z, Scrimegour D, Spendlove I, Ellis IO, Scholefield JH, Durrant LG (2005) Evidence that the p53 negative/Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients. World J Surg Oncol 3:47–57PubMedCrossRef
24.
Yang HB, Chow NH, Sheu BS, Chan SH, Chien CH, Su IJ (1999) The role of bcl-2 in the progression of the colorectal adenoma-carcinoma sequence. Anticancer Res 19:727–730PubMed
25.
Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vivo and in vitro. Oncogene 9:1799–1805PubMed
26.
Haldar S, Negrini M, Monne M, Sabbioni S, Crose CM (1994) Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54:2095–2097PubMed
27.
28.
Hao XP, Ilyas M, Talbot IC (1997) Expression of Bcl-2 and p53 in the colorectal adenoma-carcinoma sequence. Pathobiology 65:140–145PubMed
29.
Miyashita T, Harigai M, Hanada M, Reed JC (1994) Identification of a p53 dependent negative response element in the bcl-2 gene. Cancer Res 54:3131–3135PubMed
30.
Jen J, Kim H, Piantadosi S, Liu ZF, Levitt RC, Sistonen P, Kinzler KW, Vogelstein B, Hamilton SR (1994) Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331:213–221PubMedCrossRef
31.
Ayhan A, Yasui W, Yokozaki H, Seto M, Ueda R, Tahara E (1994) Loss of heterozygosity at the bcl-2 gene locus and expression of bcl-2 in human gastric and colorectal carcinomas. Jpn J Cancer Res 85:584–591PubMed
32.
Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerises in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell 74:609–619PubMedCrossRef
33.
Hao XP, Frayling IM, Sgouros JG, Du MQ, Willcocks TC, Talbot IC, Tomlinson IP (2002) The spectrum of p53 mutations in colorectal adenomas differs from that in colorectal carcinomas. Gut 50:834–839PubMedCrossRef
34.
Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U (1994) The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86:499–504PubMedCrossRef
35.
Joensuu H, Pylkkanen L, Toikkanen S (1994) Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145:1191–1198PubMed
36.
Nakamura S, Akazawa K, Kinukawa N, Yao T, Tsuneyoshi M (1996) Inverse correlation between the expression of bcl-2 and p53 proteins in primary gastric lymphoma. Hum Pathol 27:225–233PubMedCrossRef
37.
Hussein MR, Al-Sabae TM, Georgis MN (2004) Analysis of Bcl-2 and p53 protein expression in non-Hodgin’s lymphoma. Ann Oncol 12:1849–1850CrossRef
38.
Klobusicka M, Kusenda J, Babusikova O (2002) Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients. Neoplasma 49:387–393PubMed
39.
Hao XP, Gunther T, Roessner A, Price AB, Talbot IC (1998) Expression of mdm2 and p53 in epithelial neoplasms of the colorectum. Mol Pathol 51:26–29PubMedCrossRef
40.
Abdel-Fattah G, Yoffe B, Krishnan B, Khaoustov V, Itani K (2000) Mdm2/p53 protein expression in the development of colorectal adenocarcinoma. J Gastrointest Surg 4:109–114PubMedCrossRef
41.
Ofner D, Maier H, Reidmann B (1995) Histochemically detectable p53 and mdm2 oncoprotein expression in colorectal carcinoma: prognostic significance. J Clin Pathol 48:12–16CrossRef
42.
Theodorakis P, D’Sa-Eipper C, Subramanian T, Chinnadurai G (1996) Unmasking of a proliferation-restraining activity of the antiapoptosis protein EBV BHRF1. Oncogene 12:1707–1713PubMed
43.
Tsutsui S, Yasuda K, Suzuki K, Takeuchi H, Nishizaki T, Higashi H, Era S (2006) Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer. BMC Cancer 6:187–193PubMedCrossRef
44.
Papatheodoridis GV, Triantafyllou K, Tzouvala M, Paspatis G, Xourgias V, Karamanolis DG (1996) Characteristics of rectosigmoid adenomas as predictors of synchronous advanced proximal colon neoplasms. Am J Gastroenterol 91:1809–1813PubMed
45.
Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G (2003) Grading of distal colorectal adenomas as predictors for proximal colonic neoplasia and choice of endoscope in population screening: prevention study (NORCCAP) experience from the Norwegian Colorectal Cancer. Gut 52:398–403PubMedCrossRef
46.
Atkin WS, Morson BC, Cuzick J (1992) Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 326:658–662PubMedCrossRef
47.
Dave S, Hui S, Kroenke K, Imperiale TF (2003) Is the distal hyperplastic polyps a marker for proximal neoplasia? a systematic review. J Gen Intern Med 18:128–137PubMedCrossRef
48.
Lewis JD, Ng K, Hung KE, Bilker WB, Berlin JA, Brensinger C, Rustgi AK (2003) Detection of proximal adenomatous polyps with screening sigmoidoscopy: a systemic review and meta-analysis of screening colonoscopy. Arch Intern Med 163:413–420PubMedCrossRef
Metadata
Title
Potential Role of Apoptosis and Apoptotic Regulatory Proteins in Colorectal Neoplasia: Correlations with Clinico-Pathological Parameters and Survival
Authors
Maria Tzouvala
Andreas C. Lazaris
George V. Papatheodoridis
Chariklia Kouvidou
Thomas G. Papathomas
Nikos Kavantzas
Ioannis Elemenoglou
Demetrios G. Karamanolis
Emmanouil Agapitos
Publication date
01-02-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-9857-6

Other articles of this Issue 2/2008

Digestive Diseases and Sciences 2/2008 Go to the issue

Original Paper

The Janeway Gastrostomy Tube for Recurrent Gastric Intubations: A Novel and Simple Animal Model

Letter to the Editor

Dermatomyositis Accompanied by Bleeding Esophageal Diverticula or Intramural Pseudodiverticulosis?

Original Paper

Delayed Complications after Placement of Self-Expanding Stents in Malignant Esophageal Obstruction: Treatment Strategies and Survival Rate

Original Paper

Omeprazole Inhibits Natural Killer Cell Functions

Original Paper

Hyperbaric Oxygen Therapy Is as Effective as Dexamethasone in the Treatment of TNBS-E-Induced Experimental Colitis

Letter to the Editor

Brunner’s Gland Hamartomas: Endoscopic Submucosal Dissection versus Snare Polypectomy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits